Skip to main content

Table 4 Outcomes, follow-up and changes in tumor sizes after SAE

From: Efficacy and safety of selective renal arterial embolization in renal angiomyolipoma: a prospective single-center study

Variables

Data

Mean follow-up ± SD (min–max), months

6.91 ± 3.41 (1.0–12.0)

Maximum diameter of AMLs, cm

 

Before SAE, median (min–max)

13.9 (6.60–25.5)

After SAE, median (min–max)

10.7 (4.7–30.0)

Maximum diameter reduction

 

Median (min–max), cm

1.8 (− 7.2–7.0)

Median (min–max), (%)

16.0 (− 32.58–59.83)

Volume of AMLs, cc

 

Before SAE, median (min–max)

715.91 (134.18–3533.81)

After SAE, median (min–max)

283.89 (37.33–6322.45)

Volume reduction

 

Median (min–max), cc

213.1 (− 3266.67–1711.69)

Median (min–max), (%)

48.44 (− 106.9–94.17)

Serum creatinine level, mL/min

 

Before SAE, median (min–max)

0.8 (0.5–2.8)

After SAE, median (min–max)

0.7 (0.40–3.1)

Hemoglobin level, g/dL

 

Before SAE, mean ± SD

9.84 ± 2.29

After SAE, mean ± SD

10.72 ± 1.44

Leucocytic count (103/uL)

 

Before SAE, mean ± SD

10.56 ± 3.43

After SAE, mean ± SD

10.07 ± 3.38

Hospital stay duration, median (min–max) days

6.0 (1.0–20.0)